| abstract |
The present invention provides a recombinant humanized monoclonal antibody or antigen-binding fragment thereof against programmed cell death receptor-1 (PD-1), which can be used for tumor or cancer immunotherapy. The present invention also provides a nucleic acid sequence encoding the antibody or antigen-binding fragment thereof, vectors, pharmaceutical compositions and kits containing the nucleic acid sequence. |